CRCamiel Rosman

Camiel Rosman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camiel Rosman has a total of 441 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Are age, comorbidity, and frailty associated with complications after minimally invasive esophagectomy? A multicenter cohort study.

    by Ruben O Wissing, Eric Matthée, Nikolaj S Baranov, Sander Ubels, Camiel Rosman, Frans van Workum, Bastiaan R Klarenbeek

    Perioperative risks in older, comorbid, and frail patients undergoing open esophagectomy are increased, whereas these risks remain uncertain for minimally invasive esophagectomy (MIE). This study investigates the relationship between age, comorbidity, frailty, and complications after MIE. Prospective data from the randomized ICAN trial were used, which compared intrathoracic and cervical anastomosis in adult esophageal cancer patients undergoing MIE. Patients were categorized by age (<75 and ≥ 75 years), comorbidity (ASA, Charlson Comorbidity index (CCI), Cumulative Illness Rating Scale for Geriatrics (CIRS-G)), and frailty (TOPICS-MDS ≥0.20). Primary outcome: severe complications (Clavien-Dindo grade ≥ 3a). Secondary outcomes: overall complications, hospital and intensive care unit (ICU) length of stay (LOS), and hospital readmission. Multivariable regression analysis adjusted for gender and anastomosis location. Among 245 patients, 87 (35.5%) had severe complications. Eighteen (7.3%) were aged ≥75 years, 49 (20%) had ASA ≥3, 41 (16.7%) had CCI ≥2, median CIRS-G score was 3 (IQR 2.0), and 14 patients (5.7%) were frail. In multivariable regression, age, ASA ≥3, CCI ≥2, and CIRS-G were not independently associated with severe complications, overall complications, readmission, hospital or ICU LOS. Multivariable regression analysis for frailty was limited by the small number of frail patients. Older and comorbid patients did not experience higher rates of severe complications following MIE, suggesting that they may be considered safe candidates for MIE despite their age. When selected according to current clinical practice, age, and comorbidity alone should not rule out surgical consideration.


  • Open Access

    International Society for Diseases of the Esophagus consensus on the diagnosis and treatment of anastomotic leak after esophagectomy

    by Sanne K Stuart, Jobbe M G Lemmens, Grard A P Nieuwenhuijzen, Richard P T Evans, Sivesh K Kamarajah, Ian Y H Wong, Bas P L Wijnhoven, Ewen A Griffiths, Bastiaan R Klarenbeek, Sander Ubels, et al.

    SUMMARY: Background: Anastomotic leak (AL) is a severe complication after esophagectomy. Guidelines for the management of AL are lacking. This study aimed to develop a consensus statement for managing AL after esophagectomy. A three-stage modified Delphi study was performed in collaboration with the International Society for Diseases of the Esophagus Guidelines Committee. In Stage 1, a scoping systematic review was performed to identify available literature used to formulate Delphi statements. Stage 2 involved a two-round Delphi survey, distributed globally to surgeons and gastroenterologists. Consensus was defined as ≥80% (strong) (dis)agreement on a Delphi statement. During Stage 3 (guideline development), an international expert panel formulated clinical recommendations based on Delphi consensus and assigned strength in line with Grading of Recommendations Assessment, Development, and Evaluation principles. A clinical care algorithm was developed based on these recommendations. Of 5.843 articles screened, 118 were included to form Delphi statements. The Delphi survey was completed by 106 respondents in the first round and 136 in the second. Based on Delphi consensus and expert panel discussions, 12 diagnostic recommendations were formulated, covering clinical signs, biochemical tests, and imaging strategies. 11 recommendations were formulated regarding treatment strategies, including indications and techniques for supportive care, drainage and defect closure. This led to the development of a clinical care algorithm. A consensus statement for the diagnosis and treatment of AL after esophagectomy was developed. This may aid clinicians in the diagnosis and management of AL and provide a tool for standardizing clinical practice with the aim to improve patient outcomes.


  • Open Access

    A cost-effectiveness analysis of the effect of hospital variation in the probability of providing treatment with curative intent in potentially curable esophageal and gastric cancer patients

    by Saskia P M Truijen, Pauline A J Vissers, Grard A P Nieuwenhuijzen, Maurice J C van der Sangen, Peter D Siersema, Marije Slingerland, Nadia H Mohammad, Laurens V Beerepoot, Mark I van Berge Henegouwen, Pieter C van der Sluis, et al.

    Summary: For potentially curable esophageal cancer (EC) and gastric cancer (GC) patients, the probability of treatment with curative intent varies between hospitals and is associated with survival. This study examines the effect of this variation on health economics outcomes and cost-effectiveness. We performed a cost-effectiveness analysis from a societal perspective in potentially curable EC or GC patients selected from the Netherlands Cancer Registry. Resource use and costs were estimated for each treatment strategy from diagnosis until five years follow-up using a top–down costing method. Hospitals were divided into tertiles of low, medium, or high probability of treatment with curative intent using multilevel multivariable logistic regression. The primary outcome was the incremental cost-effectiveness ratio (ICER). Mean total costs per patient was not significantly different between low, medium, and high probability hospitals for EC (n = 9468) (€47,532 vs. €47,384 vs. €47,825), while for GC (n = 3085) costs were significantly lower in low compared to medium and high probability hospitals (€27,759 vs. €30,183 vs. €29,589, both P < 0.001). Costs per quality adjusted life year (QALY) were slightly lower in high probability hospitals for both EC and GC (EC: €29,181 vs. €28,646 vs. €27,659, GC: €25,003 vs. €22,505 vs. €20,495). ICERs were highest for high vs. medium probability hospitals for EC (€4900/QALY) and for medium vs. low probability hospitals for GC (€10,539/QALY). Variation in treatment with curative intent between hospitals affects health economics outcomes to a limited extent. Although all hospital comparisons were cost-effective, for the highest QALY gain, it is recommended to treat potentially curable patients as in high probability hospitals.


  • Open Access

    Intrathoracic versus cervical anastomosis after totally or hybrid minimally invasive transthoracic oesophagectomy for oesophageal cancer: cost-effectiveness analysis alongside the randomized ICAN trial

    by Eric Matthée, Sander Ubels, Bastiaan Klarenbeek, Moniek H P Verstegen, Gerjon Hannink, Frans van Workum, Camiel Rosman, Janneke P C Grutters, ICAN Collaborative Research Group, Mark I van Berge Henegouwen, et al.

    Background: There is a worldwide trend towards minimally invasive oesophagectomy with intrathoracic anastomosis in oesophageal cancer surgery. Minimally invasive oesophagectomy with intrathoracic anastomosis has been shown to result in fewer anastomotic leaks, but cost-effectiveness is yet to be established. The aim of this study was to determine the cost-effectiveness of transthoracic minimally invasive oesophagectomy with intrathoracic anastomosis compared with cervical anastomosis. Methods: A prospective economic evaluation was performed alongside the ICAN trial, a randomized clinical superiority trial. Patients with mid/distal oesophageal or gastro-oesophageal junction cancer were randomly assigned to transthoracic minimally invasive oesophagectomy with either intrathoracic or cervical anastomosis. Quality-adjusted life-years, mean healthcare, and societal costs were assessed for both groups at 9 and 21 months after surgery. Results: A total of 245 patients randomized for transthoracic minimally invasive oesophagectomy with either intrathoracic (122) or cervical (123) anastomosis were included in the cost-effectiveness analysis. After 9 months, the intrathoracic group yielded 0.58 (95% confidence interval (c.i.) 0.55 to 0.61) quality-adjusted life-years per patient, compared with 0.56 (0.52 to 0.58) quality-adjusted life-years for the cervical group. After 9 months, both mean healthcare costs (20 573 (95% c.i. 17 623 to 24 177) versus 28 039 (23 574 to 33 116) euros), and societal costs (24 590 (21 237 to 29 074) versus 33 383 (27 885 to 38 805) euros), per patient were lower in the intrathoracic anastomosis group. Similarly, at 21 months no statistically significant difference was found (mean difference 0.08 (−0.05 to 0.2) quality-adjusted life-years), whereas minimally invasive oesophagectomy with intrathoracic anastomosis was less costly than that with cervical anastomosis (mean difference −9930 (−16 301 to −2521) euros). The higher costs in the cervical anastomosis group were mainly due to longer lengths of stay owing to complications. Conclusion: Transthoracic minimally invasive oesophagectomy with intrathoracic anastomosis was found to be cost-effective compared with transthoracic minimally invasive oesophagectomy with cervical anastomosis.


  • Open Access

    Minimally Invasive transCervical oEsophagectomy (MICE) for oesophageal cancer: prospective cohort study (IDEAL stage 2A)

    by Richard J M T Vercoulen, Linde van Veenendaal, Irene F Kramer, Merlijn Hutteman, Atsushi Shiozaki, Hitoshi Fujiwara, Camiel Rosman, Bastiaan R Klarenbeek

    Background: Minimally invasive transcervical oesophagectomy is a surgical technique that offers radical oesophagectomy without the need for transthoracic access. The aim of this study was to evaluate the safety and feasibility of the minimally invasive transcervical oesophagectomy procedure and to report the refinement of this technique in a Western cohort. Methods: A single-centre prospective cohort study was designed as an IDEAL stage 2A study. Patients with oesophageal cancer (cT1b–4a N0–3 M0) who were scheduled for oesophagectomy with curative intent were eligible for inclusion in the study. The main outcome parameter was the postoperative pulmonary complication rate and the secondary outcomes were the anastomotic leakage, recurrent laryngeal nerve palsy, and R0 resection rates, as well as the lymph node yield. Results: In total, 75 patients underwent minimally invasive transcervical oesophagectomy between January 2021 and November 2023. Several modifications to the surgical technique were registered, evaluated, and implemented in the context of IDEAL stage 2A. A total of 12 patients (16%) had postoperative pulmonary complications, including pneumonia (4 patients) and pleural effusion with drainage or aspiration (8 patients). Recurrent laryngeal nerve palsy was observed in 33 of 75 patients (44%), with recovery in 30 of 33 patients (91%). A total of 5 of 75 patients (7%) had anastomotic leakage. The median number of resected lymph nodes was 29 (interquartile range 22–37) and the R0 resection rate was 96% (72 patients). Conclusion: Introducing minimally invasive transcervical oesophagectomy for oesophageal cancer in a Dutch institution is associated with a low rate of postoperative pulmonary complications and a high rate of temporary recurrent laryngeal nerve palsy.


  • Open Access

    Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

    by Julie F. M. Geerts, Charlène J. van der Zijden, Pieter C. van der Sluis, Manon C. W. Spaander, Grard A. P. Nieuwenhuijzen, Camiel Rosman, Hanneke W. M. van Laarhoven, Rob H. A. Verhoeven, Bas P. L. Wijnhoven, Sjoerd M. Lagarde, et al.

    Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods: Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015–2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77–1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09–1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08–1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05–2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.


  • A Video-Based Procedure-Specific Competency Assessment Tool for Minimally Invasive Esophagectomy

    by Mirte H. M. Ketel, Bastiaan R. Klarenbeek, Yassin Eddahchouri, Edward Cheong, Miguel A. Cuesta, Elke van Daele, Lorenzo E. Ferri, Suzanne S. Gisbertz, Christian A. Gutschow, Michal Hubka, et al.

    Importance Minimally invasive esophagectomy (MIE) is a complex procedure with substantial learning curves. In other complex minimally invasive procedures, suboptimal surgical performance has convincingly been associated with less favorable patient outcomes as assessed by peer review of the surgical procedure. Objective To develop and validate a procedure-specific competency assessment tool (CAT) for MIE. Design, Setting, and Participants In this international quality improvement study, a procedure-specific MIE-CAT was developed and validated. The MIE-CAT contains 8 procedural phases, and 4 quality components per phase are scored with a Likert scale ranging from 1 to 4. For evaluation of the MIE-CAT, intraoperative MIE videos performed by a single surgical team in the Esophageal Center East Netherlands were peer reviewed by 18 independent international MIE experts (with more than 120 MIEs performed). Each video was assessed by 2 or 3 blinded experts to evaluate feasibility, content validity, reliability, and construct validity. MIE-CAT version 2 was composed with refined content aimed at improving interrater reliability. A total of 32 full-length MIE videos from patients who underwent MIE between 2011 and 2020 were analyzed. Data were analyzed from January 2021 to January 2023. Exposure Performance assessment of transthoracic MIE with an intrathoracic anastomosis. Main Outcomes and Measures Feasibility, content validity, interrater and intrarater reliability, and construct validity, including correlations with both experience of the surgical team and clinical parameters, of the developed MIE-CAT. Results Experts found the MIE-CAT easy to understand and easy to use to grade surgical performance. The MIE-CAT demonstrated good intrarater reliability (range of intraclass correlation coefficients [ICCs], 0.807 [95% CI, 0.656 to 0.892] for quality component score to 0.898 [95% CI, 0.846 to 0.932] for phase score). Interrater reliability was moderate (range of ICCs, 0.536 [95% CI, −0.220 to 0.994] for total MIE-CAT score to 0.705 [95% CI, 0.473 to 0.846] for quality component score), and most discrepancies originated in the lymphadenectomy phases. Hypothesis testing for construct validity showed more than 75% of hypotheses correct: MIE-CAT performance scores correlated with experience of the surgical team (r = 0.288 to 0.622), blood loss (r = −0.034 to −0.545), operative time (r = −0.309 to −0.611), intraoperative complications (r = −0.052 to −0.319), and severe postoperative complications (r = −0.207 to −0.395). MIE-CAT version 2 increased usability. Interrater reliability improved but remained moderate (range of ICCs, 0.666 to 0.743), and most discrepancies between raters remained in the lymphadenectomy phases. Conclusions and Relevance The MIE-CAT was developed and its feasibility, content validity, reliability, and construct validity were demonstrated. By providing insight into surgical performance of MIE, the MIE-CAT might be used for clinical, training, and research purposes.


  • Open Access

    Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma

    by Sofie P G Henckens, Dajia Liu, Suzanne S Gisbertz, Marianne C Kalff, Maarten C J Anderegg, David Crull, Freek Daams, Annette D van Dalsen, Jan Willem T Dekker, Marc J van Det, et al.

    This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site.


  • Open Access

    Stoma-free survival after anastomotic leak following rectal cancer resection: worldwide cohort of 2470 patients

    by Nynke G Greijdanus, Kiedo Wienholts, Sander Ubels, Kevin Talboom, Gerjon Hannink, Albert Wolthuis, F Borja de Lacy, Jérémie H Lefevre, Michael Solomon, Matteo Frasson, et al.

    Background: The optimal treatment of anastomotic leak after rectal cancer resection is unclear. This worldwide cohort study aimed to provide an overview of four treatment strategies applied. Methods: Patients from 216 centres and 45 countries with anastomotic leak after rectal cancer resection between 2014 and 2018 were included. Treatment was categorized as salvage surgery, faecal diversion with passive or active (vacuum) drainage, and no primary/secondary faecal diversion. The primary outcome was 1-year stoma-free survival. In addition, passive and active drainage were compared using propensity score matching (2 : 1). Results: Of 2470 evaluable patients, 388 (16.0 per cent) underwent salvage surgery, 1524 (62.0 per cent) passive drainage, 278 (11.0 per cent) active drainage, and 280 (11.0 per cent) had no faecal diversion. One-year stoma-free survival rates were 13.7, 48.3, 48.2, and 65.4 per cent respectively. Propensity score matching resulted in 556 patients with passive and 278 with active drainage. There was no statistically significant difference between these groups in 1-year stoma-free survival (OR 0.95, 95 per cent c.i. 0.66 to 1.33), with a risk difference of −1.1 (95 per cent c.i. −9.0 to 7.0) per cent. After active drainage, more patients required secondary salvage surgery (OR 2.32, 1.49 to 3.59), prolonged hospital admission (an additional 6 (95 per cent c.i. 2 to 10) days), and ICU admission (OR 1.41, 1.02 to 1.94). Mean duration of leak healing did not differ significantly (an additional 12 (−28 to 52) days). Conclusion: Primary salvage surgery or omission of faecal diversion likely correspond to the most severe and least severe leaks respectively. In patients with diverted leaks, stoma-free survival did not differ statistically between passive and active drainage, although the increased risk of secondary salvage surgery and ICU admission suggests residual confounding.


  • Open Access

    Stoma-free Survival After Rectal Cancer Resection With Anastomotic Leakage

    by Nynke G. Greijdanus, Kiedo Wienholts, Sander Ubels, Kevin Talboom, Gerjon Hannink, Albert Wolthuis, Francisco B. de Lacy, Jérémie H. Lefevre, Michael Solomon, Matteo Frasson, et al.

    Objective: To develop and validate a prediction model (STOMA score) for 1-year stoma-free survival in patients with rectal cancer (RC) with anastomotic leakage (AL). Background: AL after RC resection often results in a permanent stoma. Methods: This international retrospective cohort study (TENTACLE-Rectum) encompassed 216 participating centres and included patients who developed AL after RC surgery between 2014 and 2018. Clinically relevant predictors for 1-year stoma-free survival were included in uni and multivariable logistic regression models. The STOMA score was developed and internally validated in a cohort of patients operated between 2014 and 2017, with subsequent temporal validation in a 2018 cohort. The discriminative power and calibration of the models’ performance were evaluated. Results: This study included 2499 patients with AL, 1954 in the development cohort and 545 in the validation cohort. Baseline characteristics were comparable. One-year stoma-free survival was 45.0% in the development cohort and 43.7% in the validation cohort. The following predictors were included in the STOMA score: sex, age, American Society of Anestesiologist classification, body mass index, clinical M-disease, neoadjuvant therapy, abdominal and transanal approach, primary defunctioning stoma, multivisceral resection, clinical setting in which AL was diagnosed, postoperative day of AL diagnosis, abdominal contamination, anastomotic defect circumference, bowel wall ischemia, anastomotic fistula, retraction, and reactivation leakage. The STOMA score showed good discrimination and calibration (c-index: 0.71, 95% CI: 0.66–0.76). Conclusions: The STOMA score consists of 18 clinically relevant factors and estimates the individual risk for 1-year stoma-free survival in patients with AL after RC surgery, which may improve patient counseling and give guidance when analyzing the efficacy of different treatment strategies in future studies.